Join us online for APIC’s inaugural 2019 Virtual Conference on December 12. This ground-breaking new event gives you an unique chance to access the fundamental learning that all IPs need. With a variety of sessions offered over four hours, you’ll hear from thought leaders and practitioners in the field of IPC in an interactive learning platform that’s convenient, cost-effective, and accessible from any device! Sessions include:
The human and financial costs of treating surgical site infections (SSIs) are increasing. The number of surgical procedures performed in the U.S. continues to rise, and surgical patients are initially seen with increasingly complex co-morbidities. It is estimated that approximately half of SSIs are deemed preventable using evidence-based strategies. There are specific requirements to minimize the spread of microorganisms and maintain sterility in the operating room (OR) environment. This presentation will review the challenges and issues as well as guidelines and standards affecting the OR setting. You will learn:
As hospitals and LTC facilities age or seek ways to improve their patient care capabilities, there is often an increase in construction and maintenance activities. During these projects, the IP must remain focused on patient safety and the Infection Control Risk Assessment (ICRA).
This session will cover procedures that are essential to assuring patient safety during construction and maintenance activities. Topics to be discussed will include everything from completing an ICRA permit to how to conduct project rounding to identify what is right and what is wrong. This session will also briefly cover the use of a handheld particle counter that can be of benefit to the IP during a construction project. Discussions will revolve around how a particle counter can be used to enhance construction project rounding and monitoring. You will learn how to:
The success of most medical acute and chronic life-sustaining therapies across all ages and patient populations is dependent on reliable vascular access. Though critical to the provision of life-saving medical therapies, vascular access devices (VADs) are associated with significant risk. Under-reported, under-recognized, and most often ignored, are the infections associated with peripheral vascular access devices (PVADs), such as short peripheral catheters (SPC) and midline catheters (MC). From 2008 to 2011, hospitals across the nation made significant progress in preventing CLABSI, achieving ~50% reduction in those three years. However, the rate of CLABSI has not improved since 2015 despite concerted efforts. The expectation is that CLABSI will decrease significantly by 2020. If IPs cannot identify unrecognized risk factors such as PVAD-BSI that contribute to the flat line in progress, this task may be insurmountable.
Consider the answers to these questions: Do you know your institution’s PVAD incidence rate for BSI? How many of your CLABSIs are PVAD-BSI? How do you diagnose PVAD-BSI? Will clinically indicated SPC site changes increase the risk for SPC-BSI and what are the legal implications? Have you considered that non-sterile insertion of SPCs may increase BSI risk? Have you considered the lack of sterile SPC insertion as a legal liability when all other VADs are inserted with sterile technique? Do we want to continue to ignore the risk of perpetuating antibiotic resistance by the increasing need to treat the very devices we use to treat non-device related infections? Is the use of MCs to avoid CLABSI in the best interest of the patient? You will get answers to these questions and will learn how to:
Staff from the Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention discuss recent activities related to outbreaks of water-associated pathogens and trends in water management programs. This session focuses on water-associated outbreaks, drawing on such data sources PRB outbreak consultations about water-associated outbreaks, and NHSN annual facility survey data for hospitals and nursing homes about current status of water management plans and control activities. You will learn how to:
The emerging drug-resistant fungus Candida auris is a yeast that breaks the mold. From an infection prevention perspective, it behaves more like bacteria in its ability to colonize skin, survive on healthcare surfaces, and spread between patients, causing outbreaks.
This session will cover what we know—and what we don’t—about C. auris and current recommendations for early detection and infection prevention. In particular, it will cover the similarities and differences in containing spread of C. auris vs. other multidrug-resistant organisms and address common myths. You will learn: